Company profilePharmaceutical#268 of 1,318 in Pakistan5 DRAP alerts

PLIVA PAKISTAN (PVT) LIMITED

Pharmaceutical company · 69 brands · 84 molecules

Ranked #77 of 156 companies in Antianemic, Iron Preparations

69 registered products 29 pharmaceutical brands 84 distinct molecules 5 DRAP alerts

Company overview

69
registered products
29
pharmaceutical brands
84
distinct molecules
12
therapeutic classes
5
DRAP alerts

PLIVA PAKISTAN (PVT) LIMITED is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 69 product registrations across 84 distinct molecules. Its portfolio is concentrated in Antianemic, Iron Preparations and Antihistamines For Systemic Use. DRAP has issued 5 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Therapeutic classes

Antianemic, Iron Preparations · 2Antihistamines For Systemic Use · 1Nasal Preparations · 1Vitamin B12 Plain · 1Cardiac Therapy · 1Antispasmodic & Anticholinergic · 1Vaccine · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Anti-Infective, Ophthalmologicals · 1Vitamin C · 1Vitamin B Complex Plain & With Vitamin C · 1Beta Blocking Agent · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official2 products · Rs 626.92 – Rs 679.22
Median across source: Rs 653.07

Regulatory record

5 alerts in the DRAP feed we track.

Recall Alert: Drug Product; Plivil 25mg Injection (Batch # 847) by M/s. Pliva Pakistan, (P
2023-09-07
Rapid Alert; Drug Product: Falsified Phenobar 30mg Tablets identified in the Market
2023-06-07
Recall Alert: Drug Product; Chloroquine Injection (Batch # 201238) by M/s Mehran Internati
2023-02-27
Drug Safety Alert: Increased Risk of Cardiovascular Events with Co-administration and Inte
2022-11-29
Safety Alert of Falsified Chloroquine Products Circulating in the WHO Region of Africa
2020-04-15

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for PLIVA

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.